posts tagged as Drug pricing

BDO Knows Healthcare Spring 2016 Newsletter

In the Spring 2016 edition of the BDO Knows Healthcare newsletter, we focus on the impact of changing reimbursements across the healthcare spectrum: on investors, providers and pharmaceutical companies. read more

By David Friend | February 11, 2016

As Drug Price Scrutiny Rises, Pressure Builds to Define Value

Drug pricing is one of today’s most hotly debated and deeply complex topics, influencing and being influenced by the healthcare and pharmaceutical industries’ paradigm shift from fee-for-service to value-based care and... read more

By William Bithoney | November 10, 2015

Pharmacy Benefits Managers: A Driving Force for Deals

Walgreens’ recent announcement to acquire Rite Aid generated plenty of buzz, with analysts suggesting that the deal was really about pharmacy benefits managers (PBMs). Controlling drug costs has become a major focus for providers... read more

By William Bithoney | October 02, 2015

340B Program Guidance Finally Sets Sail

For several years, hospital administrators and clinicians have been anxiously awaiting proposed new “mega” regulations affecting the federal 340B drug program. After hitting a bump in the road earlier this year, the Health... read more

By Venson Wallin | February 03, 2015

The 340B “Mega-Reg” Is Gone, But Not Forgotten

Parting is such sweet sorrow. So says William Shakespeare in Romeo and Juliet. The Health Resources and Services Administration (HRSA) would no doubt agree with old Bill when it comes to the 340B Program’s proposed &ldquo... read more

New Rules for Discounted Drug Program

The 340B program was initially enacted into law in 1992 as a part... read more